Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

LivaNova to Announce Second-Quarter 2022 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Announce Second-Quarter 2022 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2022 results on Wednesday, August 3, 2022 at 1

Premier Inc. Honors Indiana Recovery Home for Women with National Award and $100,000 Prize: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. Honors Indiana Recovery Home for Women with National Award and $100,000 Prize


The BreakAway, a nonprofit dedicated to helping women recover from the disease of addiction in New Albany, IN, has received the 2022 Monroe E. Trout Premier Cares Award and a $100,000 cash prize

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
ICON plc Schedules Second Quarter 2022 Earnings Conference Call: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON plc Schedules Second Quarter 2022 Earnings Conference Call


ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the second quarter 2022 after the

Henry Ford Health Wins 2022 Premier Alliance Excellence Award: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Henry Ford Health Wins 2022 Premier Alliance Excellence Award


Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has named Henry Ford Health, an integrated nonprofit health system providing a full continuum of services

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer


Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Annual General Shareholders’ Meeting 2022:
Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2022: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2022: Sonova shareholders approve all motions of the Board of Directors
AMN Healthcare Services, Inc. Announces $250 Million Share Repurchase Program
AMN Healthcare Services, Inc. Announces $250 Million Share Repurchase Program


The Board of Directors (the “Board”) of AMN Healthcare Services, Inc. (NYSE: AMN, the “Company”) authorized an additional $250 million under the Company’s repurchase program for the company’s

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
LivaNova Elects Peter Wilver to Board of Directors: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Elects Peter Wilver to Board of Directors


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Peter Wilver has been elected to the Board of Directors, effective immediately. His election

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A


Charles River Laboratories International, Inc. (NYSE: CRL) and ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in vivo gene replacement

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Laboratories to Participate in Jefferies and William Blair Conferences: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories to Participate in Jefferies and William Blair Conferences


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies Healthcare Conference on Wednesday, June 8th, at 10:00 a.m. ET, and at the William

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer


Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage

Chemed Corporation to Present at the Jefferies 2022 Healthcare Conference:
Chemed Corporation to Present at the Jefferies 2022 Healthcare Conference


Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2022 Healthcare Conference on Thursday, June 9, 2022, at approximately 8:00 a.m. (ET) in New York

US-Gesundheitsbehörde CDC empfiehlt Einsatz digitaler PCR-Technologie für Abwassertests zur Überwachung von Infektionskrankheiten – einschließlich COVID-19-Ausbrüchen
US-Gesundheitsbehörde CDC empfiehlt Einsatz digitaler PCR-Technologie für Abwassertests zur Überwachung von Infektionskrankheiten – einschließlich COVID-19-Ausbrüchen


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die jüngste Empfehlung des National Wastewater Surveillance Systems (NWSS) des US-amerikanischen Centers for Disease Control and

U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomed an endorsement from the National Wastewater Surveillance System (NWSS) of the U.S. Centers for Disease

AMN Healthcare Survey: Most Healthcare Facilities Using Locum Tenens Physicians to Fill Vacancies
AMN Healthcare Survey: Most Healthcare Facilities Using Locum Tenens Physicians to Fill Vacancies


Nearly 90% of healthcare facilities used locum tenens physicians and/or advanced practice professionals to fill gaps in their staffs last year, according to a new survey from AMN Healthcare, the

Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial